Press Resease

Macular Degeneration Treatment Market - Global Industry Analysis

Macular Degeneration Treatment Market: by Drug Class (Anti-VEGFs and Other Drugs); by Indication (Wet Age-related Macular Degeneration (wAMD) and Dry Age-related Macular Degeneration (dAMD)); by Distribution Channel (Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2025

Published Date: 29-Nov-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-5117 Status : Published

Global demand for macular degeneration treatment market was valued at approximately USD 6.38 billion in 2018, and is expected to generate revenue of around USD 10.07 billion by end of 2025, growing at a CAGR of around 6.8% between 2019 and 2025.

Description

The report covers forecast and analysis for the macular degeneration treatment market on a global and regional level. The study provides historic data from 2016 along with forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the macular degeneration treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the macular degeneration treatment market on a global as well as regional level.

According to the report, global demand for macular degeneration treatment market was valued at approximately USD 6.38 billion in 2018, and is expected to generate revenue of around USD 10.07 billion by end of 2025, growing at a CAGR of around 6.8% between 2019 and 2025.

In order to give the users of this report a comprehensive view on the macular degeneration treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the macular degeneration treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the macular degeneration treatment market on global and regional basis.

The study provides a crucial view on the macular degeneration treatment by segmenting the market based on drug class, indication, distribution channel and region. All the segments of macular degeneration treatment market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.

Macular degeneration is one of major eye disorder and a leading cause of vision loss, affecting people more than cataracts and glaucoma together. Currently, macular degeneration cannot be cured i.e. it is an incurable disease. Deterioration of central portion of the retina called macula leads to macular degeneration. Retina records images we see and signal is sent to brain via optic nerve. Macula is responsible for central vision focusing in the eye. Macula also controls our ability to recognize colors or faces, ability to read, and see objects with fine details.

The demand for macular degeneration treatment market is driven by increasing prevalence of eye disorders, age related macular degeneration and increasing geriatric population across the globe. Additionally, focus of major pharmaceutical manufacturers on development of novel treatment options, increasing awareness, government initiatives to support R&D, and increasing healthcare spending are other factors that boost the market growth. However, growing off-label use of products may hamper the market growth. Emerging markets with unmet medical needs and increasing geriatric population are expected to bring new growth avenues for major market players working in the global macular degeneration treatment.

Based on drug class, global macular degeneration treatment market is bifurcated into anti-vascular endothelial growth factor (VEGFs), and other drugs. Anti-VEGFs accounted for largest market share in 2018 and are projected to witness rapid CAGR over the forecast period as they are considered as gold standard therapy for macular degeneration.

Based on indication market is segmented into Wet Age-related Macular Degeneration (wAMD) and Dry Age-related Macular Degeneration (dAMD). wAMD indication segment accounted for largest market share in 2018 due to large number of ongoing research activities for novel therapy development for wAMD. Favorable reimbursement policies may further boost this growth over the forecast period.

The distribution channel segment is divided ambulatory surgical centers, ophthalmic clinics and hospitals. Hospitals dominated the macular degeneration treatment market to ease of access to hospitals and availability of technologically advanced facilities. Ophthalmic clinics are projected to witness rapid growth over the forecast period.

North America dominated the global macular degeneration treatment market in 2018. Increasing prevalence of eye disorders, increasing geriatric population, favorable reimbursement policies, and growing awareness are factors driving the market in this region. Europe was second largest regional market. Availability of developed infrastructure, increasing awareness and prevalence of eye disorders are some of the factors that fuel market growth in this region. Latin America is projected to witness moderate growth over the forecast period. Asia Pacific region is estimated to witness highest CAGR for macular degeneration treatment market in the coming years. Increasing prevalence of age related macular degeneration in geriatric population, increasing disposable income, health care spending, and growing awareness are factors promoting macular degeneration treatment market growth in Asia Pacific. Middle East and Africa will see considerable growth in coming years.

Major players included in the report are Valeant Pharmaceuticals, Santen Pharmaceuticals, Pfizer, Inc., Sanofi, F. Hoffmann-La Roche, StemCells, Neurotech Pharmaceuticals, Ophthotech Corporation, Bayer AG, GlaxoSmithKline, Allergan and Novartis among others.

The report segment of global macular degeneration treatment market as follows:

Global Macular Degeneration Treatment Market: By Drug Class

  • Anti-vascular Endothelial Growth Factor (VEGFs)
  • Other Drugs

Global Macular Degeneration Treatment Market: By Indication

  • Wet Age-related Macular Degeneration (wAMD)
  • Dry Age-related Macular Degeneration (dAMD)

Global Macular Degeneration Treatment Market: By Distribution Channel

  • Ambulatory Surgical Centers
  • Ophthalmic Clinics
  • Hospitals

Global Macular Degeneration Treatment Market: By Region

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Macular Degeneration Treatment Market, 2016 - 2025, (USD Million)
    • 2.2. Macular Degeneration Treatment Market: Snapshot
  • Chapter 3. Global Macular Degeneration Treatment Market - Industry Analysis
    • 3.1. Macular Degeneration Treatment Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Macular Degeneration
      • 3.2.2. Increasing Geriatric Population
    • 3.3. Restraints
      • 3.3.1. Off-label Use of Drugs
    • 3.4. Opportunity
      • 3.4.1. Emerging Markets
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by drug class segment
      • 3.6.2. Market attractiveness analysis by indication segment
      • 3.6.3. Market attractiveness analysis by distribution channel segment
      • 3.6.4. Market attractiveness analysis by regional segment
  • Chapter 4. Global Macular Degeneration Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global macular degeneration treatment market: company market share analysis, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New drug class launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Macular Degeneration Treatment Market - Drug Class Segment Analysis
    • 5.1. Global macular degeneration treatment market overview: by drug class
      • 5.1.1. Global macular degeneration treatment market revenue share, by drug class, 2018 and 2025
    • 5.2. Anti-vascular Endothelial Growth Factor (VEGFs)
      • 5.2.1. Global macular degeneration treatment market by Anti-vascular Endothelial Growth Factor (VEGFs), 2016-2025 (USD Million)
    • 5.3. Other Drugs
      • 5.3.1. Global macular degeneration treatment market by Other Drugs, 2016-2025 (USD Million)
  • Chapter 6. Global Macular Degeneration Treatment Market - Indication Segment Analysis
    • 6.1. Global macular degeneration treatment market overview: by indication
      • 6.1.1. Global macular degeneration treatment market revenue share, by indication, 2018 and 2025
    • 6.2. Wet Age-related Macular Degeneration (wAMD)
      • 6.2.1. Global macular degeneration treatment market by Wet Age-related Macular Degeneration (wAMD), 2016-2025 (USD Million)
    • 6.3. Dry Age-related Macular Degeneration (dAMD)
      • 6.3.1. Global macular degeneration treatment market by Dry Age-related Macular Degeneration (dAMD), 2016-2025 (USD Million)
  • Chapter 7. Global Macular Degeneration Treatment Market - Distribution Channel Segment Analysis
    • 7.1. Global macular degeneration treatment market overview: by distribution channel
      • 7.1.1. Global macular degeneration treatment market revenue share, by distribution channel, 2018 and 2025
    • 7.2. Ambulatory Surgical Centers
      • 7.2.1. Global macular degeneration treatment market by Ambulatory Surgical Centers, 2016-2025 (USD Million)
    • 7.3. Ophthalmic Clinics
      • 7.3.1. Global macular degeneration treatment market by Ophthalmic Clinics, 2016-2025 (USD Million)
    • 7.4. Hospitals
      • 7.4.1. Global macular degeneration treatment market by Hospitals, 2016-2025 (USD Million)
  • Chapter 8. Global Macular Degeneration Treatment Market - Regional Analysis
    • 8.1. Global macular degeneration treatment market overview: by region
      • 8.1.1. Global macular degeneration treatment market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America macular degeneration treatment market, by country, 2016-2025 (USD Million)
      • 8.2.2. North America macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 8.2.3. North America macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
      • 8.2.4. North America macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.2.5.2. The U.S. macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.2.5.3. The U.S. macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.2.6.2. Rest of North America macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.2.6.3. Rest of North America macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe macular degeneration treatment market, by country, 2016-2025 (USD Million)
      • 8.3.2. Europe macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 8.3.3. Europe macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
      • 8.3.4. Europe macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.3.5.2. U.K. macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.3.6.2. France macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.3.6.3. France macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.7. Germany
        • 8.3.7.1. Germany macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.3.7.2. Germany macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.3.7.3. Germany macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.3.8.2. Rest of Europe macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.3.8.3. Rest of Europe macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific macular degeneration treatment market, by country, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
      • 8.4.4. Asia Pacific macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.5. China
        • 8.4.5.1. China macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.4.5.2. China macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.4.5.3. China macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.6. Japan
        • 8.4.6.1. Japan macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.4.6.2. Japan macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.4.6.3. Japan macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.7. India
        • 8.4.7.1. India macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.4.7.2. India macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.4.7.3. India macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America macular degeneration treatment market, by country, 2016-2025 (USD Million)
      • 8.5.2. Latin America macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 8.5.3. Latin America macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
      • 8.5.4. Latin America macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.5.5.2. Brazil macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.5.5.3. Brazil macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 8.5.6.2. Rest of Latin America macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
        • 8.5.6.3. Rest of Latin America macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.6. Middle East & Africa
      • 8.6.1. Middle East & Africa macular degeneration treatment market, 2016-2025 (USD Million)
      • 8.6.2. Middle East & Africa macular degeneration treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 8.6.3. Middle East & Africa macular degeneration treatment market revenue, by indication, 2016-2025 (USD Million)
      • 8.6.4. Middle East & Africa macular degeneration treatment market revenue, by distribution channel, 2016-2025 (USD Million)
  • Chapter 9. Company Profiles
    • 9.1. Valeant Pharmaceuticals
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Drug Class Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Pfizer, Inc.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Drug Class Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Santen Pharmaceuticals
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Drug Class Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Sanofi
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Drug Class Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. F. Hoffmann-La Roche
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Drug Class Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Developments
    • 9.6. StemCells
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Drug Class Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Developments
    • 9.7. Neurotech Pharmaceuticals
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Drug Class Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Developments
    • 9.8. Ophthotech Corporation
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Drug Class Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Developments
    • 9.9. Bayer AG
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Drug Class Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Developments
    • 9.10. GlaxoSmithKline
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Drug Class Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Developments
    • 9.11. Novartis
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Drug Class Portfolio
      • 9.11.4. Business Strategy
      • 9.11.5. Recent Developments
    • 9.12. Allergan
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Drug Class Portfolio
      • 9.12.4. Business Strategy
      • 9.12.5. Recent Developments

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social